BioCentury
ARTICLE | Emerging Company Profile

Sugar-coated bugs

Centauri aims to take alphamers beyond antibiotic resistance

April 4, 2016 7:00 AM UTC

Centauri Therapeutics Ltd.'s alphamer technology recruits a population of pre-existing, endogenous polyclonal antibodies to kill antibiotic-resistant bacteria.

Centauri acquired the technology from Altermune Technologies LLC, a company founded by PCR inventor Kary Mullis. According to Centauri CEO Mike Westby, Altermune was a virtual company that essentially held the IP of the academic project. "We are now translating what was validated science into generating drugs which will treat antimicrobial-resistant infections," he told BioCentury. ...